These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 2581861)
1. Behaviour of antithrombin III abnormalities in the crossed immunoelectrophoresis system. Girolami A; Cappellato G; Vicarioto MA; Vergolani A; Traverso R Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(1):159-64. PubMed ID: 2581861 [TBL] [Abstract][Full Text] [Related]
2. Further investigations on antithrombin III in the plasmas of patients with the abnormality of antithrombin III Budapest. Sas G; Pepper DS; Cash JD Thromb Diath Haemorrh; 1975 Jun; 33(3):564-72. PubMed ID: 1154312 [TBL] [Abstract][Full Text] [Related]
3. Antithrombin III Trento. A 'new' congenital AT III abnormality with a peculiar crossed-immunoelectrophoretic pattern in the absence of heparin. Girolami A; Marafioti F; Rubertelli M; Vicarioto MA; Cappellato G; Mazzuccato M Acta Haematol; 1984; 72(2):73-82. PubMed ID: 6208738 [TBL] [Abstract][Full Text] [Related]
4. Antithrombin III molecular variants with defective binding to heparin or to serine proteases: evidence of two different abnormal patterns identified by crossed immunoelectrofocusing. Leone G; De Stefano V; Ferrelli R; Teofili L; Tengborn L; Vahtera E; Bizzi B Thromb Haemost; 1988 Aug; 60(1):8-12. PubMed ID: 3187949 [TBL] [Abstract][Full Text] [Related]
5. Antithrombin III Alger: a new homozygous AT III variant. Fischer AM; Cornu P; Sternberg C; Mériane F; Dautzenberg MD; Chafa O; Beguin S; Desnos M Thromb Haemost; 1986 Apr; 55(2):218-21. PubMed ID: 3715788 [TBL] [Abstract][Full Text] [Related]
6. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding. Jørgensen M; Petersen LC; Thorsen S J Lab Clin Med; 1984 Aug; 104(2):245-56. PubMed ID: 6747440 [TBL] [Abstract][Full Text] [Related]
7. Immunoelectrophoretic evidence of a thrombin-induced abnormality in a new variant of hereditary dysfunctional antithrombin III (AT III 'Vicenza'). Barbui T; Finazzi G; Rodeghiero F; Dini E Br J Haematol; 1983 Aug; 54(4):561-5. PubMed ID: 6871107 [TBL] [Abstract][Full Text] [Related]
8. Antithrombin III "Northwick Park": a variant antithrombin with normal affinity for heparin but reduced heparin cofactor activity. Howarth DJ; Samson D; Stirling Y; Seghatchian MJ Thromb Haemost; 1985 Jun; 53(3):314-9. PubMed ID: 4049307 [TBL] [Abstract][Full Text] [Related]
9. Crossed immunoelectrophoresis as applied to studies on complex formation. The binding of heparin to antithrombin III and the antithrombin III--thrombin complex. Andersson LO; Engman L; Henningsson E J Immunol Methods; 1977; 14(3-4):271-81. PubMed ID: 557071 [TBL] [Abstract][Full Text] [Related]
10. Studies of heparin binding to antithrombin III by crossed immunoelectrophoresis. Barrowcliffe TW Thromb Haemost; 1980 Feb; 42(5):1434-45. PubMed ID: 7368150 [TBL] [Abstract][Full Text] [Related]
11. Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto. Okajima K; Ueyama H; Hashimoto Y; Sasaki Y; Matsumoto K; Okabe H; Inoue M; Araki S; Takatsuki K Thromb Haemost; 1989 Feb; 61(1):20-4. PubMed ID: 2749590 [TBL] [Abstract][Full Text] [Related]
12. Antithrombin Oslo: type Ib classification of the first reported antithrombin-deficient family, with a review of hereditary antithrombin variants. Hultin MB; McKay J; Abildgaard U Thromb Haemost; 1988 Jun; 59(3):468-73. PubMed ID: 3055413 [TBL] [Abstract][Full Text] [Related]
13. Antithrombin III Geneva: a hereditary abnormal AT III with defective heparin cofactor activity. de Moerloose PA; Reber G; Vernet P; Minazio P; Bouvier CA Thromb Haemost; 1987 Apr; 57(2):154-7. PubMed ID: 3603409 [TBL] [Abstract][Full Text] [Related]
14. Characterization of an abnormal antithrombin (Milano 2) with defective thrombin binding. Tripodi A; Krachmalnicoff A; Mannucci PM Thromb Haemost; 1986 Dec; 56(3):349-52. PubMed ID: 3563966 [TBL] [Abstract][Full Text] [Related]
15. AT III Barcelona: a familial quantitative-qualitative AT III deficiency. Grau E; Fontcuberta J; Félez J; de Diego I; Soto R; Rutllant ML Thromb Haemost; 1988 Feb; 59(1):13-7. PubMed ID: 3363529 [TBL] [Abstract][Full Text] [Related]
16. Microheterogeneity of antithrombin III: effect of single amino acid substitutions and relationship with functional abnormalities. De Stefano V; Leone G; Mastrangelo S; Lane DA; Girolami A; de Moerloose P; Sas G; Abildgaard U; Blajchman M; Rodeghiero F Blood Coagul Fibrinolysis; 1994 Feb; 5(1):7-15. PubMed ID: 8180341 [TBL] [Abstract][Full Text] [Related]
17. Antithrombin III, the major modulator of intravascular coagulation, is synthesized by human endothelial cells. Chan TK; Chan V Thromb Haemost; 1981 Aug; 46(2):504-6. PubMed ID: 7302889 [TBL] [Abstract][Full Text] [Related]
18. Antithrombin III Padua: a "new" congenital antithrombin III abnormality with normal or near normal activity, normal antigen, abnormal migration and no thrombotic disease. Girolami A; Pengo V; Cappellato G; Vianello C; Procidano M; Cartei C Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(1):98-111. PubMed ID: 6192061 [TBL] [Abstract][Full Text] [Related]
19. Antithrombin III (AT III) Padua2: a "new" congenital abnormality with defective heparin co-factor activities but no thrombotic disease. Girolami A; Fabris F; Cappellato G; Sainati L; Boeri G Blut; 1983 Aug; 47(2):93-103. PubMed ID: 6871478 [TBL] [Abstract][Full Text] [Related]
20. Antithrombin III in full-term and pre-term newborn infants: three cases of neonatal diagnosis of AT III congenital defect. De Stefano V; Leone G; De Carolis MP; Ferrelli R; De Carolis S; Pagano L; Tortorolo G; Bizzi B Thromb Haemost; 1987 Jun; 57(3):329-31. PubMed ID: 3660333 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]